NCT04541706View on ClinicalTrials.gov

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

July 20, 2022

Study Completion Date

July 20, 2022

Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

Lorlatinib

Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.

Trial Locations (12)

110085

Rajiv Gandhi Cancer Institute And Research Centre, New Delhi

122001

Artemis hospital, Gurugram

380016

The Gujarat Cancer and Research Institute, Ahmedabad

380054

Hemato Oncology Clinic Ahmedabad Pvt. Ltd, Ahmedabad

401107

Bhaktivedanta Hospital and Research Institute, Thāne

411001

Grant Medical Foundation, Ruby Hall Clinic, Pune

411004

Sahyadri Clinical Research and Development Center, Pune

Sahyadri Super Speciality Hospital, Pune

422009

Apex Wellness Hospital, Nashik

441108

National Cancer Institute, Nagpur

500082

Yashoda Hospital, Hyderabad

700160

Tata Medical Center, Kolkata

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04541706 - Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | Biotech Hunter | Biotech Hunter